Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain

Table 4 Correction of general and control variables associated to use of acetyl salicylic acid in primary and secondary prevention.

Correction of logistic model	Primary prevention n = 3,273			Secondary prevention n = 867			Total n = 4,140
Variables	OR	p	CI	OR	p	CI	OR	p	CI
Age	1.01	0.011	1.00–1.02	0.98	ns	-	1.02	0.000	1.01–1.03
Sex (males)	0.98	ns	-	1.04	ns	-	0.80	0.006	0.68–0.94
Number of CVRFs	1.14	0.013	1.03–1.27	1.03	ns	-	1.16	0.001	1.06–1.26
Total cholesterol	0.89	ns	-	1.50	0.039	1.02–2.21	1.30	0.005	1.08–1.55
LDL-C	1.42	0.017	1.06–1.88	0.83	ns	-	1.29	0.012	1.04–1.62
Glycated HbA1c	1.51	0.000	1.22–1.89	1.07	ns	-	1.47	0.000	1.18–1.79

CVRFs: cardiovascular risk factors; LDL-C: low density lipoprotein cholesterol; OR: odds ratio adjusted by use of acetyl salicylic acid; CI: 95% confidence intervals. Control values incorporated into the final model: total cholesterol (<200 mg/dL), LDL-C (<100 mg/dL), and glycated hemoglobin A1c (<6.5%), p: statistical significance

ISSN: 2731-4553